CoChat

The Role of Endogenous Incretin Secretion as Amplifier of Glucose-Stimulated Insulin Secretion in Healthy Subjects and Patients With Type 2 Diabetes

Open access

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

In order to quantify the role of incretins in first- and second-phase insulin secretion (ISR) in type 2 diabetes mellitus (T2DM), a double-blind, randomized study with 12 T2DM subjects and 12 healthy subjects (HS) was conducted using the hyperglycemic clamp technique together with duodenal nutrition perfusion and intravenous infusion of the glucagon-like peptide 1 (GLP-1) receptor antagonist exendin(9-39). Intravenous glucose alone resulted in a significantly greater first- and second-phase ISR in HS compared with T2DM subjects. Duodenal nutrition perfusion augmented both first- and second-phase ISR but first-phase ISR more in T2DM subjects (approximately eight- vs. twofold). Glucose-related stimulation of ISR contributed only 20% to overall ISR. Infusion with exendin(9-39) significantly reduced first- and second-phase ISR in both HS and T2DM subjects. Thus, both GLP-1 and non–GLP-1 incretins contribute to the incretin effect. In conclusion, both phases of ISR are impaired in T2DM. In particular, the responsiveness to glucose in first-phase ISR is blunted. GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) secretions are unaltered. The absolute incretin effect is reduced in T2DM; its relative importance, however, appears to be increased, highlighting its role as an important amplifier of first-phase ISR in T2DM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db11-1701

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1. Overview on study design. Red arrows indicate the blood samples for measuring plasma hormones; red asterisks indicate the time points of blood samples for glucose measurement. The asterisk in the term “glucose*” represents the time points of blood samples for glucose measurement that are indicated as asterisks in contrast to the arrows, which indicate the blood samples for measuring plasma hormones. (A high-quality color representation of this figure is available in the online issue.)
FIG. 1. Overview on study design. Red arrows indicate the blood samples for measuring plasma hormones; red asterisks indicate the time points of blood samples for glucose measurement. The asterisk in the term “glucose*” represents the time points of blood samples for glucose measurement that are indicated as asterisks in contrast to the arrows, which indicate the blood samples for measuring plasma hormones. (A high-quality color representation of this figure is available in the online issue.)CC BY-NC-ND · PubMed Central
FIG. 2. Plasma insulin (A and B) and C-peptide (C and D) in response to hyperglycemic isoglycemic clamp experiments with intravenous (IV) saline plus duodenal meal (blue triangles), exendin(9-39) (ex[9-39]) IV plus duodenal meal (yellow squares), and isoglycemic IV glucose experiments without intraduodenal meal perfusion (red circles) in HS (A and C) and patients with T2DM (B and D). Blood glucose concentrations are shown in A and B (black and white symbols). n = 12 per group; mean ± SEM. See Tables 2 and 3 for statistical analysis.
FIG. 2. Plasma insulin (A and B) and C-peptide (C and D) in response to hyperglycemic isoglycemic clamp experiments with intravenous (IV) saline plus duodenal meal (blue triangles), exendin(9-39) (ex[9-39]) IV plus duodenal meal (yellow squares), and isoglycemic IV glucose experiments without intraduodenal meal perfusion (red circles) in HS (A and C) and patients with T2DM (B and D). Blood glucose concentrations are shown in A and B (black and white symbols). n = 12 per group; mean ± SEM. See Tables 2 and 3 for statistical analysis.CC BY-NC-ND · PubMed Central
FIG. 3. Plasma insulin (A and B), incretin effect (C and D), and percentage contribution of the incretin effect to the total insulin response (E and F) in response to hyperglycemic isoglycemic clamp experiments during first-phase ISR (A, C, and E) and second-phase ISR (B, D, and F) with intravenous (IV) isoglycemic glucose experiments without intraduodenal meal perfusion (isoglycemic fasting control, white bars), with saline IV plus duodenal meal (black bars), and with exendin(9-39) (ex[9-39]) IV plus duodenal meal (striated bars) in HS and patients with T2DM. n = 12 per group; mean ± SEM of incremental AUC. *P < 0.05 vs. isoglycemic fasting control; #P < 0.05 vs. saline IV plus duodenal meal. See Tables 2 and 3 for further statistical analysis.
FIG. 3. Plasma insulin (A and B), incretin effect (C and D), and percentage contribution of the incretin effect to the total insulin response (E and F) in response to hyperglycemic isoglycemic clamp experiments during first-phase ISR (A, C, and E) and second-phase ISR (B, D, and F) with intravenous (IV) isoglycemic glucose experiments without intraduodenal meal perfusion (isoglycemic fasting control, white bars), with saline IV plus duodenal meal (black bars), and with exendin(9-39) (ex[9-39]) IV plus duodenal meal (striated bars) in HS and patients with T2DM. n = 12 per group; mean ± SEM of incremental AUC. *P < 0.05 vs. isoglycemic fasting control; #P < 0.05 vs. saline IV plus duodenal meal. See Tables 2 and 3 for further statistical analysis.CC BY-NC-ND · PubMed Central
FIG. 4. Plasma GLP-1 (A and B) and GIP (C and D) concentration in response to hyperglycemic isoglycemic clamp experiments with intravenous (IV) saline plus duodenal meal (blue triangles) or exendin(9-39) (ex[9-39]) IV plus duodenal meal (yellow squares) and isoglycemic IV glucose experiments without intraduodenal meal perfusion (red circles) in HS (A and C) and patients with T2DM (B and D). n = 12 per group; mean ± SEM. See Table 3 for statistical analysis.
FIG. 4. Plasma GLP-1 (A and B) and GIP (C and D) concentration in response to hyperglycemic isoglycemic clamp experiments with intravenous (IV) saline plus duodenal meal (blue triangles) or exendin(9-39) (ex[9-39]) IV plus duodenal meal (yellow squares) and isoglycemic IV glucose experiments without intraduodenal meal perfusion (red circles) in HS (A and C) and patients with T2DM (B and D). n = 12 per group; mean ± SEM. See Table 3 for statistical analysis.CC BY-NC-ND · PubMed Central
FIG. 5. Plasma glucagon concentration in response to hyperglycemic isoglycemic clamp experiments with intravenous (IV) saline plus duodenal meal (blue triangles) or exendin(9-39) (ex[9-39]) IV plus duodenal meal (yellow squares) and isoglycemic IV glucose experiments without intraduodenal meal perfusion (red circles) in HS (A) and patients with T2DM (B). n = 12 per group; mean ± SEM. See Table 3 for statistical analysis.
FIG. 5. Plasma glucagon concentration in response to hyperglycemic isoglycemic clamp experiments with intravenous (IV) saline plus duodenal meal (blue triangles) or exendin(9-39) (ex[9-39]) IV plus duodenal meal (yellow squares) and isoglycemic IV glucose experiments without intraduodenal meal perfusion (red circles) in HS (A) and patients with T2DM (B). n = 12 per group; mean ± SEM. See Table 3 for statistical analysis.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Schirra, 2008, The efficacy of exendin(9-39)amide as a GLP-1 receptor antagonist in human, Gut, 57, A85

Cited by

See all 73

Metadata

Authors
Woerle, H. J., Carneiro, L., Derani, A., Göke, B., & Schirra, J.
Affiliations
LMU Klinikum (DE)
Corresponding author
Schirra, Jörg
Venue
Diabetes
Published
2012-08-17
Volume
61
Issue
9
Pages
2349-2358
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2029355071
Cited by
73
References
41
Citations by year
2024: 1 · 2023: 2 · 2021: 7 · 2020: 1 · 2019: 4 · 2018: 2 · 2017: 8 · 2016: 10 · 2015: 10 · 2014: 13 · 2013: 14 · 2012: 1
FWCI
9.75
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Deutsche Forschungsgemeinschaft
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
incretins, glucose-stimulated insulin secretion, type 2 diabetes, first-phase insulin secretion, second-phase insulin secretion, glucagon-like peptide-1, exendin-9-39, glucose-dependent insulinotropic polypeptide, incretin effect, hyperglycemic clamp
MeSH terms
Glucagon-Like Peptide-1 Receptor, Insulin Secretion, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Gastric Inhibitory Polypeptide, Glucagon, Glucose, Humans, Insulin, Male, Middle Aged, Peptide Fragments, Glucose Clamp Technique, Receptors, Glucagon, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.